AQST
NASDAQAquestive Therapeutics Inc.
News · 26 weeks58+25%
2026-04-192026-10-11
Mix2690d
- Insider9(35%)
- SEC Filings8(31%)
- Other6(23%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Aquestive Therapeutics Inc.4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 3 filed by Aquestive Therapeutics Inc.3 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- SECSEC Form 8-K filed by Aquestive Therapeutics Inc.8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for the
- SECSEC Form 8-K filed by Aquestive Therapeutics Inc.8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PREton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal FilmDifferentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient market research demonstrated strong preference for buccal film, with 71% of surveyed patients preferring film versus 13% for nasal spray, assuming equivalent efficacyAnticipated commercial launch in April 2027, subject to final FDA approval, provides a potential near-term growth opportunity and new commercial platform in neurologyLIBERVANT has received Orphan Drug Designation and has issued patent protection extending into 2038, with additional patent applications pending with
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aquestive Therapeutics Inc.SCHEDULE 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Strengthens Board of Directors with Appointment of Richard DalyAppoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Rich Daly to the Company’s Board of Directors, effective October 14, 2026. Mr. Daly has three decades of leadership experience in large and small biopharmaceutical com
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual FilmResubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Anaphylm™ (dibutepinephrine) subling
- INSIDERPresident and CEO Barber Daniel sold $120,487 worth of shares (25,000 units at $4.82), decreasing direct ownership by 4% to 652,317 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Commercial Officer Korczynski Sherry exercised 8,750 shares at a strike of $2.65 and sold $45,675 worth of shares (8,750 units at $5.22) as part of a pre-agreed trading plan (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief People Officer Boyd Peter E. exercised 2,293 in-the-money shares at a strike of $0.96, increasing direct ownership by 0.81% to 284,024 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERPresident and CEO Barber Daniel exercised 91,743 in-the-money shares at a strike of $0.96, increasing direct ownership by 16% to 677,317 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Operating Officer Jung Cassie exercised 4,587 in-the-money shares at a strike of $0.96, increasing direct ownership by 2% to 206,833 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- PRAquestive Therapeutics to Participate in Upcoming September Investor ConferencesWARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows: 2026 Wells Fargo Healthcare Conference: available to host investor meetings on Tuesday, September 8thCantor Healthcare Conference: fireside chat at 3:20 pm ET and available to host investor meetings on Wednesday, September 9thCiti’s 2026 Biopharma Back to School Summit: available to host investor
- INSIDERPresident and CEO Barber Daniel sold $107,168 worth of shares (25,000 units at $4.29), decreasing direct ownership by 4% to 585,574 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Commercial Officer Korczynski Sherry covered exercise/tax liability with 2,714 shares, decreasing direct ownership by 1% to 235,689 units (SEC Form 4) (tax withholding)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- SECSEC Form 10-Q filed by Aquestive Therapeutics Inc.10-Q - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateSuccessfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues pre-launch medical affairs activities and payer engagementOn track to begin ex-U.S. filings of Anaphylm in Q4 2026Company to host investor call on August 12, 2026, at 8:00 a.m. ET WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the s
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual FilmHuman factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK resultsRevised packaging design reduced median time to open pouch from 17 seconds in the previous human factors study to 3 secondsRevised instructions for use reduced incorrect film placement from previous human factors validation study by over 80% Top-of-tongue PK arm showed clinically meaningful pharmacodynamic (PD) results WARREN, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing me
AQST FAQ
7 questionsWhat does Aquestive Therapeutics Inc. do?
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The...Where does AQST stock trade?
Aquestive Therapeutics Inc. (AQST) is listed on NASDAQ.What sector and industry is AQST in?
Aquestive Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aquestive Therapeutics Inc. go public?
Aquestive Therapeutics Inc. (AQST) completed its IPO in 2018.What are analysts saying about AQST?
Aquestive Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $800.00 price target on 2026-04-24. Recent price targets range from $700.00 to $1700.00.What companies are similar to AQST?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AQST side-by-side with any of them on Quantisnow.How can I track AQST on Quantisnow?
Quantisnow aggregates Aquestive Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AQST to receive live email and push alerts on every new disclosure.